Search

Displaying results 1191 - 1200 of 1723 in total
  1. Drug

    Afamelanotide

    go.drugbank.com/drugs/DB04931
    Approved

    A187202,A187205] Afamelanotide is currently the only approved drug therapy used in the management of erythropoietic protoporphyria, having received approval in the EU in December 2014[L9119] and subsequent FDA

  2. Drug

    Abiraterone

    go.drugbank.com/drugs/DB05812
    ApprovedInvestigational

    [A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April,[A260880] July,[L47745] and September 2011,[A260880] respectively.

  3. Drug

    Faricimab

    go.drugbank.com/drugs/DB15303
    ApprovedInvestigational

    [L43085] On April 9, 2026, the FDA approved an updated label that extended faricimab treatment for macular edema following retinal vein occlusion (RVO) beyond six months.[L40026] … [A225985, A225990, A225995, A226000, A226005, A226010] Faricimab was approved by the FDA on January 28, 2022, and is currently marketed under the trademark VABYSMO by Genentech, Inc.

  4. Drug

    Avatrombopag

    go.drugbank.com/drugs/DB11995
    ApprovedInvestigational

    [F95] Avatrombopag was first approved by the FDA in May 2018 for use in adults with chronic liver disease who are scheduled to undergo a procedure. … [L2932] In July 2025, the FDA expanded approval to include a new pediatric formulation, Doptelet Sprinkle (avatrombopag oral granules), specifically designed for children aged one to less than six years

  5. Drug

    Tarlatamab

    go.drugbank.com/drugs/DB17256
    ApprovedInvestigational

    [L50743] Tarlatamab-dlle was approved by the FDA in May 2024 for use in patients who have failed previous round of platinum-based chemotherapy,[L50743,L50748] becoming the first DLL3-targeting bispecific

  6. Drug

    Veligrotug

    go.drugbank.com/drugs/DB18976
    Approved

    [L63929] The FDA approved veligrotug-vvze on June 26, 2026, for the treatment of thyroid eye disease regardless of disease activity or duration.[L63798,L63929]

  7. Drug

    Turoctocog alfa

    go.drugbank.com/drugs/DB09109
    Approved

    [A31504] It was developped by Novo Nordisk and FDA approved in October 16, 2013.[L1104]

  8. Drug

    Cerliponase alfa

    go.drugbank.com/drugs/DB13173
    ApprovedInvestigational

    [L51319] On April 27, 2017, cerliponase alfa was first approved by the FDA as the first treatment for neuronal ceroid lipofuscinosis type 2 (CLN2), also known as TPP1 deficiency.

  9. Drug

    Orlistat

    go.drugbank.com/drugs/DB01083
    ApprovedInvestigational

    It was approved by the FDA for use in combination with a reduced-calorie diet in 1999.

  10. Drug

    Viloxazine

    go.drugbank.com/drugs/DB09185
    ApprovedInvestigationalWithdrawn

    In April 2021, an extended-release formulation of viloxazine under the brand name QELBREE was approved by the FDA for the treatment of attention deficit hyperactivity disorder (ADHD).[A247985]